세계 마이크로톰 시장 규모는 2025-2032년 예측 기간 동안 CAGR 6.13%로 성장할 것으로 예상됩니다. 마이크로톰에 대한 수요는 주로 암, 감염, 죽상동맥경화증, 심근경색, 심근증과 같은 심혈관질환, 천식, 만성폐쇄성폐질환(COPD)과 같은 호흡기질환, 만성폐쇄성폐질환(COPD)과 같은 만성질환의 증가에 의해 촉진되고 있습니다. 또한, 전 세계적으로 생물 의학 연구 및 의약품 개발 활동의 확대는 마이크로톰에 대한 수요를 촉진하고 있습니다. 연구자들은 분자진단, 신약 개발, 맞춤 의료를 위해 고품질의 조직 절편을 필요로 하고 있으며, 이는 2025-2032년 예측 기간 동안 마이크로톰 시장을 견인할 것으로 예상됩니다.
마이크로톰 시장 역학
국제암연구소(International Agency for Research on Cancer, 2024)가 제공한 자료에 따르면, 2022년 전 세계적으로 약 2,000만 건의 암이 새로 등록되었습니다. 이 자료에 따르면, 등록되는 신규 암 환자 중 폐암이 250만 건을 차지해 가장 흔한 암으로 나타났습니다. 이어 유방암 230만 건, 대장암 190만 건, 위암 97만 건 순으로 나타났습니다.
Global Cancer Observatory(2024)는 2030년까지 전 세계에서 새로 발생하는 암 발병 건수가 2,000만-2,410만 건에 달할 것으로 추정하고 있습니다. 또한, 아시아가 982만 6,539명, 유럽이 447만 1,422명, 라틴아메리카-카리브해가 155만 1,060명, 아프리카가 118만 5,216명일 것으로 예상하고 있습니다.
암의 진단과 치료는 정확한 조직 검사에 크게 의존하기 때문에 암 발병률의 증가에 따라 현미경 분석에 사용되는 고품질 조직 절편을 만들기 위해 마이크로톰을 광범위하게 사용해야 합니다. 이러한 암 환자의 급증은 마이크로톰 시장의 확대로 이어질 것입니다.
또한, 결핵, 간염, COVID-19, 진균 감염 등의 감염병 발생 시 병원체 확인, 조직 손상 정도 평가, 질병 진행 모니터링 등을 위해 생검조직의 병리조직학적 평가가 필수적입니다. 세계보건기구(WHO)가 제공한 자료에 따르면, 2023년 전 세계적으로 약 1,080만 명이 결핵에 걸릴 것으로 추정되며, 그 중 남성 600만 명, 여성 360만 명, 어린이 130만 명이 결핵에 걸릴 것으로 예상됩니다. 또한, 같은 자료에 따르면 2022년 전 세계적으로 약 2억 5,400만 명이 B형 간염, 5,000만 명이 C형 간염에 감염되어 매일 6,000명이 새롭게 바이러스성 간염에 감염되고 있습니다. 마이크로톰은 확진 진단을 위해 현미경으로 염색 및 검사하는 얇고 균일한 조직 절편을 만드는 데 매우 중요하며, 이로 인해 마이크로톰 시장 전체를 견인하고 있습니다.
따라서, 위의 모든 요인들이 예측 기간 동안 마이크로톰 시장을 견인할 것으로 예상됩니다.
그러나 냉동 절편화 및 레이저 마이크로다이세션과 같은 대체 샘플 조제 기술의 가용성으로 인해 기존 마이크로톰에 대한 의존도가 감소할 수 있으며, 이는 최종사용자 기반을 제한하는 요인으로 작용하여 예측 기간 동안 마이크로톰 시장의 성장을 억제할 것으로 전망입니다.
북미가 전체 마이크로톰 시장을 독식할 것으로 예상
북미는 2024년 마이크로톰 시장에서 전체 지역 중 가장 높은 점유율을 차지할 것으로 예상됩니다. 이는 북미의 암 환자 및 감염성 질환의 지속적인 증가에 기인합니다. 또한, 고급 의료 인프라와 이미 사용 가능한 첨단 장비, 첨단 암 진단 검사 및 스크리닝에 대한 전망 확대, 병리 검사실에 대한 유리한 상환 정책, 의료비 증가, 이 지역 내 다수의 시장 기업 존재는 북미 마이크로톰 시장의 성장을 촉진할 것으로 예상됩니다.
National Cancer Institute(2024)는 2024년 말까지 미국에서 200만 명의 암 환자가 새로 진단될 것으로 추정하고 있습니다. 또한 전립선암, 폐암, 대장암이 전체 남성 암 진단의 약 48%를 차지할 것으로 추정됩니다. 가장 발병률이 높은 암은 유방암, 폐암, 대장암으로 전체 신규 암 진단의 약 51%를 차지할 것으로 예상됩니다.
세계의 마이크로톰 시장에 대해 조사 분석했으며, 시장 규모와 예측, 최근 3년간의 제품/기술 개발, 주요 기업, 시장 기회 등의 정보를 전해드립니다.
Microtome Market by Product (Microtome [Rotary Microtome, Vibrating Microtome, and Others] and Accessories [Blades and Knives, Cooling Clamp, and Others]), Technology (Fully Automated, Semi-Automated, and Manual), End-User (Hospitals, Diagnostic Clinics, Academic and Research Laboratories, and Others), and Geography (North America, Europe, Asia-Pacific, and rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing cases of chronic disorders, increase in research and development activities, among others globally.
The microtome market is estimated to grow at a CAGR of 6.13% during the forecast period from 2025 to 2032. The demand for microtomes is primarily being boosted by the increasing cases of chronic disorders such as cancer, infectious disease, cardiovascular diseases, including atherosclerosis, myocardial infarction, and cardiomyopathies, respiratory disorders like asthma, chronic obstructive pulmonary disease (COPD), and others. Additionally, the expansion of biomedical research and pharmaceutical development activities worldwide is fueling the demand for microtomes. Researchers require high-quality tissue sections for molecular diagnostics, drug discovery, and personalized medicine, thus boosting the market for microtomes during the forecast period from 2025 to 2032.
Microtome Market Dynamics:
According to data provided by the International Agency for Research on Cancer (2024), in 2022, approximately 20 million new instances of cancer were registered globally. Additionally, as per the same source, lung cancer accounted for 2.5 million new cases globally, of all the registered new cancer cases, making it the most common cancer. Next in order of incidence were breast cancer with 2.3 million cases, colon cancer with 1.9 million cases, and stomach cancer with 0.97 million cases globally.
The Global Cancer Observatory (2024) estimated that the new instances of cancer globally would range from 20 million to 24.1 million by the year 2030. Moreover, it stated that Asia accounted for 9,826,539 cancer cases, Europe accounted for 4,471,422 cancer cases, LAC accounted for 1,551,060 cancer cases, and Africa accounted for 1,185,216 cancer cases.
Since cancer diagnosis and treatment rely heavily on accurate tissue examination, the rising cancer rates necessitate the widespread use of microtomes to prepare high-quality tissue sections for microscopic analysis. This surge in cancer cases translates into a larger market for microtomes.
Additionally, during outbreaks of infectious diseases such as tuberculosis, hepatitis, COVID-19, and fungal infections, histopathological evaluation of biopsied tissues becomes essential to identify the pathogen, assess the extent of tissue damage, and monitor disease progression. According to the data provided by the World Health Organization, in 2023, an estimated 10.8 million people fell ill with TB worldwide, including 6.0 million men, 3.6 million women, and 1.3 million children. Additionally, as per the same source, in 2022, an estimated 254 million people were living with hepatitis B and 50 million people were living with hepatitis C worldwide, and 6000 people were newly infected with viral hepatitis each day. Microtomes are crucial in preparing thin, uniform tissue sections that are stained and examined under microscopes for definitive diagnosis, thereby boosting the overall market of microtomes.
Therefore, all the above-mentioned factors are expected to drive the market for microtomes during the given forecast period.
However, the availability of alternative sample preparation technologies, such as cryo-sectioning and laser microdissection, could reduce the reliance on traditional microtomes, acting as factors that are expected to limit their end-user base, thus restricting the growth of the microtome market during the forecast period.
Microtome Market Segment Analysis:
Microtome Market by Product (Microtome [Rotary Microtome, Vibrating Microtome, and Others] and Accessories [Blades and Knives, Cooling Clamp, and Others]), Technology (Fully Automated, Semi-Automated, and Manual), End-User (Hospital, Diagnostic Clinics, Academic and Research Laboratories, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the technology segment of the microtome market, the fully automated category of microtome is estimated to amass a significant revenue share in the microtome market in 2024. This can be attributed to the large patient population associated with various chronic disorders and the presence of a variety of products available to this category.
Fully automated microtomes offer several advantages and diverse applications, significantly enhancing the field of histopathology. Their primary benefits are to produce consistent high quality tissue sections with minimal user intervention, ensuring precision and reproducibility. This automation reduces the risk of human error and variability, which is crucial for accurate diagnosis.
In terms of applications, fully automated microtomes are invaluable in cancer diagnostics, where they provide fine tissue sections needed for detailed examination of tumor morphology and margins. They are also extensively used in research settings to study disease mechanisms at the cellular level, contributing to the development of new treatments and therapies. These advanced instruments are employed in various medical fields, including neuropathology, dermatopathology, and cardiovascular pathology, where precise tissue sectioning is critical for studying complex structures and diagnosing conditions.
Additionally, the presence of a huge number of commercially available fully automated systems and the increasing demand for digitalization in tissue diagnostic procedures are some of the crucial factors anticipated to boost the market in the next few years. Some of the key automated products include Microtome A550, Tissue-Tek Genie, and Leica Biosystems HistoCore AUTOCUT 2550.
Therefore, the various advantages and applications provided by fully automated microtomes will contribute to the growth of this category, thereby driving the growth of the overall microtome market during the forecast period.
North America is expected to dominate the overall microtome market:
North America is expected to account for the highest proportion of the microtome market in 2024, out of all regions. This is owing to the continual increase in cancer cases and infectious diseases in the North America region. Moreover, the high-end medical infrastructure paired with readily available high-tech equipment, expanding prospects for sophisticated cancer diagnostic testing and screening, favorable reimbursement policies for pathology labs, rise in healthcare spending, presence of a large number of market players in the region are expected to drive the growth of the microtome market in North America.
The National Cancer Institute (2024) estimated that 2 million new cases of cancer will be diagnosed in the US by the end of 2024. Furthermore, it was estimated that prostate, lung, and colorectal cancers were expected to represent approximately 48% of all cancer diagnoses in men. The most prevalent cancers are breast, lung, and colorectal, which are expected to account for about 51% of all new cancer diagnoses.
According to Global Cancer Observatory's data (2024), in 2022, the US represented 89.1% of all cancer cases, and Canada represented 10.9% of all cancer cases. The reliance on microtomes for accurate tissue sectioning in cancer diagnosis and research is paramount. Microtomes are essential for producing high-quality tissue samples for identifying cancer types, understanding disease progression, and tailoring treatment plans. Consequently, the rising instances of cancer catalyze the demand for microtomes, hence propelling market growth.
According to the recently updated data provided by the Centers for Disease Control and Prevention (CDC) (2024), it was stated that 805,000 people in the US have a myocardial infarction (heart attack) every year on average. The high incidence of myocardial infarctions necessitates extensive histological examination of cardiac tissues to understand the underlying causes. Microtomes are essential in preparing thin, detailed sections of heart tissue for microscopic analysis, enabling pathologists to examine cellular structures, detect abnormalities, and evaluate the effectiveness of treatment, therefore boosting its market growth.
According to the American Lung Association data updated in April 2024, it stated that more than 34 million people were living in the US with chronic lung diseases like asthma and COPD. These disorders underscore the growing need for microtomes in diagnostic pathology because of their ability to produce high-quality lung tissue sections for microscopic analysis, which is vital for diagnosing, understanding, and treating these conditions, consequently boosting the market for microtomes.
Thus, due to the interplay of all the above-mentioned factors, it will lead to an increase in the North America microtome market growth during the forecast period from 2025 to 2032.
Microtome Market Key Players:
Some of the key market players operating in the microtome market include Thermo Fisher Scientific Inc., AGD Biomedicals Pvt. Ltd., SLEE medical GmbH, Diapath S.p.A., Leica Biosystems Nussloch GmbH, Green Leaf Scientific, MEDITE Medical GmbH, LLS ROWIAK LaserLabSolutions GmbH, Amos Scientific PTY. LTD, RWD Life Science Co., Sakura Finetek, Boeckeler Instruments, Inc., HACKER Instruments & Industries Inc., microTec Laborgerate GmbH, Bright Instrument Co Limited, JINHUA YIDI MEDICAL APPLIANCES CO., LTD, FEATHER Safety Razor Co., Ltd., Precisionary Instruments, Powered Milestone Srl, Weinkauf Medizintechnik, and others.
Recent Developmental Activities in the Microtome Market:
Key takeaways from the microtome market report study
Target audience who can benefit from this microtome market report study
Frequently Asked Questions for the Microtome Market: